Imfinzi plus tarlatamab shows survival gains in lung cancer trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Imfinzi plus tarlatamab shows survival gains in lung cancer trial

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta

September 8, 2026 9:00 AM EDT

IMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting

DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy for small cell lung cancer across stages of disease

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgens tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line... More